Cargando…
A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies
Tumor-selective viruses are a novel therapeutic approach for treating cancer. Tumor-Specific Immuno Gene Therapy (T-SIGn) vectors are tumor-selective adenoviral vectors designed to express immunomodulatory transgenes. Prolonged activated partial thromboplastin time (aPTT), associated with the presen...
Autores principales: | Khalil, Danny N., Prieto González-Albo, Isabel, Rosen, Lee, Lillie, Tom, Stacey, Andrea, Parfitt, Lola, Soff, Gerald A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999314/ https://www.ncbi.nlm.nih.gov/pubmed/36897458 http://dx.doi.org/10.1007/s10637-023-01345-8 |
Ejemplares similares
-
Xenogenic Adenoviral Vectors
por: Both, Gerald W.
Publicado: (2002) -
Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
por: Mendonça, Samir Andrade, et al.
Publicado: (2021) -
Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status
por: Chavda, Vivek P., et al.
Publicado: (2023) -
Targeted adenoviral vectors
por: Vigne, E, et al.
Publicado: (2001) -
Xenogenic Adenoviral Vectors
por: Mittal, Suresh K., et al.
Publicado: (2016)